Several published studies, including studies from our group, demonstrated the prognostic potential of CSC-related biomarkers including CD44, CD133, ALDH1A3, and c-MET for patients with HNSCC treated with radio(chemo)therapy [13,32,36,57]. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.